Systemic Lupus Erythematosus Clinical Trials 2023

What are the top hospitals conducting systemic lupus erythematosus research?

In the realm of systemic lupus erythematosus (SLE) clinical trials, top hospitals across the United States are making significant strides in understanding and treating this complex autoimmune disease. The Oklahoma Medical Research Foundation, located in Oklahoma City, takes a leading position with five ongoing SLE trials and an impressive history of 41 total trials since their first recorded investigation in 1995. Meanwhile, SUNY Upstate Medical University in Syracuse is also actively contributing to SLE research through its current participation in five clinical trials and a cumulative tally of 12 past studies dating back to their initial trial in 2008.

Notably, Tampa's reputable research site has emerged as another important player on this front, conducting four active SLE trials while having previously contributed to twelve investigations since their first recorded trial in 2007. Similarly engaged is a notable research site based out of Charlotte, which currently hosts four ongoing SLE trials and has conducted thirteen total studies since commencing their inaugural investigation into this disease's nature and potential treatments backin2008.

It is worth mentioning that NYU Langone Health from New york City may have fewer active projects than some other institutions on this list with only three current systemic lupus erythematosus clinical trials; however, they represent the cutting edge by initiating their very first study on the condition as recently as2023.

These remarkable efforts signify a collective commitment among these esteemed medical centers to improve the lives of individuals grappling with systemic lupus erythematosus. Through rigorous scientific exploration and innovative treatment approaches emerging from these clinical trials across diverse locations throughout America - ranging from bustling cities like New York to dynamic regions such as Oklahoma - researchers are dedicatedly working towards advancing our understanding of SLE alongside developing effective therapies for those affected by it worldwide

Which are the best cities for systemic lupus erythematosus clinical trials?

When it comes to systemic lupus erythematosus clinical trials, several cities have emerged as leading hubs for research and development. New york City, with its 20 active trials, explores a wide range of treatments such as Hydroxychloroquine (HCQ), Administration of CC-97540, and Arm 1: Deucravacitinib. Miami, Florida also boasts 20 ongoing studies focused on innovative approaches like Cenerimod 4 mg, ALPN-101, and GLPG3667. Additionally, Charlotte in North carolina offers 19 active trials examining treatment options including Obinutuzumab and BIIB059 Low Dose. These cities provide individuals with systemic lupus erythematosus access to cutting-edge clinical trials that may lead to improved care and better outcomes.

Which are the top treatments for systemic lupus erythematosus being explored in clinical trials?

Clinical trials for systemic lupus erythematosus are pushing boundaries to discover effective treatments. At the forefront is Cenerimod 4 mg, currently being explored in two active trials and making its debut in 2018 with one all-time trial dedicated to this condition. This promising treatment shows great potential in improving outcomes for patients battling systemic lupus erythematosus. As research progresses, there is hope that these clinical trials will bring us closer to finding more innovative therapies and ultimately providing relief for those affected by this complex autoimmune disease.

What are the most recent clinical trials for systemic lupus erythematosus?

Promising developments in the field of systemic lupus erythematosus (SLE) research are bringing hope to those affected by this challenging autoimmune disease. Recent clinical trials have introduced innovative approaches and potential treatments for SLE. These include Imvotamab, a Phase 1 trial exploring dose escalation for SLE patients, Study 3 which investigates the efficacy of Upadacitinib in treating SLE as part of its Phase 3 study, CC-97540 administration during a Phase 1 trial, Group 1's participation in a Phase 2 study focusing on SLE treatment options, and finally GLPG3667's examination through a Phase 2 trial specifically designed for individuals with SLE. With these advancements underway, there is renewed optimism that improved therapies will soon be available to enhance the lives of those living with SLE.

What systemic lupus erythematosus clinical trials were recently completed?

Several recent clinical trials have shed light on potential treatments for systemic lupus erythematosus (SLE), offering hope to those affected by this complex autoimmune disease. Notably, in February 2022, Daiichi Sankyo completed a trial investigating DS-7011a's efficacy as a therapy for SLE. Preceding this, Viela Bio concluded their trial of VIB7734 in June 2021 and Sanofi wrapped up their SAR443122 study in April 2021. These advancements follow prior breakthroughs such as Eli Lilly and Company's completion of the LY3471851 trial in August 2020 and Amgen's Rozibafusp Alfa trial concluded in February 2020. The ongoing pursuit of effective therapies reflects the commitment of researchers to better manage SLE and enhance patients' quality of life.